Aytu BioPharma Prices Upsized Public Offering Of 9.60M Shares At Effective Public Offering Price Of $1.50

Nantahala Capital Management, Stonepine Capital Management, Aytu Management, and New Institutional Shareholders Lead Financing.

DENVER, CO / ACCESS Newswire / June 6, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced the pricing of an upsized public offering of 9,600,000 shares of common stock (or prefunded warrants in lieu thereof) at an effective public offering price of $1.50. In addition, Aytu has granted the underwriters a 30-day option to purchase up to an additional 1,440,000 shares of its common stock at the public offering price.

The offering is expected to close on or about June 9, 2025, subject to the satisfaction of customary closing conditions. Gross proceeds to the Company, before deducting underwriters' fees and other offering expenses, are expected to be approximately $14.4 million. The Company intends to use the net proceeds of this offering for general corporate purposes, working capital and general and administrative expenses, and to execute on a transaction that will enable the Company to exclusively commercialize EXXUA™ (gepirone) extended-release tablets, a novel, branded, FDA-approved treatment for major depressive disorder in the United States.